Par Pharmaceutical to Present at Credit Suisse First Boston Annual Healthcare Conference
Posted on: Thursday, 10 November 2005, 15:00 CST
SPRING VALLEY, N.Y., Nov. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. will be presenting at the Credit Suisse First Boston Annual Healthcare Conference on Wednesday, November 16, at 10:30 am MST at the Arizona Biltmore Resort in Phoenix.
The audio-only live webcast will be accessible through the Credit Suisse First Boston website at http://w.on24.com/r.htm?e=17820&s=1&k=4B276281C93318C4E17CAC3C279A135E or through the Par Pharmaceutical website at http://www.parpharm.com/ . A replay will be available at the same link address for 30 days after the conference and will begin within 24 hours after the presentation.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace(R) ES, for specialty markets. Par currently manufactures, markets or licenses more than 90 prescription drugs. For press release and other company information, please visit http://www.parpharm.com/ .
Par Pharmaceutical Companies, Inc.
CONTACT: Stephen J. Mock or Cecelia C. Heer, both of Par PharmaceuticalCompanies, Inc., +1-201-802-4000
Web site: http://www.parpharm.com/
Source: PRNewswire-FirstCall
Related Articles
- Par Pharmaceutical to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
- Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
- La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent
- /C O R R E C T I O N -- Par Pharmaceutical Companies, Inc./
- Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
- Spectrum Announces Strategic Alliance With Par Pharmaceutical Companies, Inc. For Sales and Distribution of Spectrum's Generic Product Line
- KV Pharmaceutical Company to Market New Generic Drugs in U.S. Via Exclusive Deal With Gedeon Richter
- Par Pharmaceutical's Partner Receives Final Approval to Market Ribavirin Tablets
- Par Pharmaceutical To Present at CIBC World Markets 16th Annual Healthcare Conference
- Par Pharmaceutical Receives Final Approval to Market Clonazepam Orally Disintegrating Tablets
User Comments (0)
RSS Feeds